Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
Additional research highlights integration of BluePrint molecular subtyping and ImPrint immune profiling to optimize prediction of neoadjuvant treatment response in HER2-positive early-stage breast cancer
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced new data to be presented at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 29 – June 2 in Chicago. The company will present two posters highlighting how MammaPrint® (MP) + BluePrint® (BP) provide biological insights into treatment response and help further refine therapeutic decision-making for patients with early-stage breast cancer (EBC).
Poster #46 | June 1, 1:30 p.m. – 4:30 p.m. CDT | Presenter: Steven Isakoff
Association of the 70-gene assay and homologous recombination deficiency in patients with High Risk 2 breast cancers
